New cocktail of four drugs shows promise against bone marrow cancer

NCT ID NCT04009109

First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if adding two extra drugs to standard maintenance therapy can keep the cancer from coming back longer. About 79 participants will receive the drugs for 12 cycles, then continue with either one or three drugs for up to two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Gibbs Cancer Center & Research Institute/Spartanburg Regional Healthcare

    Spartanburg, South Carolina, 29303, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Northern Light Eastern Maine Medical Center

    Bangor, Maine, 04401, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68152, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

Conditions

Explore the condition pages connected to this study.